Cryopreserved Platelets (CPP) for US FDA Licensure
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), specifically the ARMY MED RES ACQ ACTIVITY under the Warfighter Protection and Acute Care Project Management Office (WPAC PMO), is issuing a Sources Sought / Request for Information (RFI) for Cryopreserved Platelets (CPP) for US FDA Licensure. The agency seeks information regarding the development and management of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets, a biologic product designed for a longer shelf life (2+ years) to enhance readiness and improve the quality of life for active-duty personnel. Responses are due by 3:00 PM ET on May 4, 2026.
Scope of Work
The DHA is interested in capabilities related to:
- Performing FDA's general recommendations and procedures for Emergency Use Authorization (EUA).
- Serving as the Investigational New Drug (IND) application #14047 holder and regulatory sponsor, managing all regulatory submissions through the Biological License Application (BLA). The estimated period of performance for EUA activities is up to sixty (60) months. DMSO CPP are formulated from γ-irradiated, leukocyte-reduced apheresis platelets, cryopreserved in DMSO at -80°C, and have shown promise in clinical studies.
Contract & Timeline
- Type: Sources Sought / Request for Information (RFI)
- Set-Aside: None specified
- Response Due: May 4, 2026, by 3:00 PM ET
- Questions Due: April 28, 2026, by 3:00 PM ET
- Published: April 28, 2026
- Place of Performance: Frederick, MD 21702, United States
Submission Instructions
Interested entities must submit:
- A white paper
- A rough order of magnitude (ROM) cost estimate
- A contact information table Submissions should not exceed ten (10) pages (excluding cover page, table of contents, tables, and charts) and must adhere to specific formatting: Times New Roman 12-point, single-spaced, 1-inch margins. Electronic submissions (Microsoft Word or searchable Adobe PDF, max 3 MB) are required.
Key Contact
- Primary Contact: Peter Mitchell
- Email for Submissions: peter.d.mitchell8.civ@health.mil
- Email Subject: "Response to RFI for Cryopreserved Platelets (CPP)."
Disclaimer
This RFI is for information and planning purposes only and does not constitute a solicitation or commitment to award a contract. The Government is not obligated to pay for submitted information. No phone calls will be accepted.